急性呼吸窘迫综合征的临床试验:挑战与机遇
本文为急性呼吸窘迫综合征(ARDS)首次描述50周年的综述。自首次描述以来,对ARDS肺损伤发病机制的认识不断深入,重点关注肺内皮和肺泡上皮损伤机制。治疗方面,肺保护性通气(潮气量6 mL/kg预测体重、平台气道压<30 cm H2O)显著降低了ARDS死亡率。对严重低氧的ARDS患者,神经肌肉阻滞和俯卧位进一步降低死亡率,可能通过延长肺保护性通气的治疗效果实现。液体保守治疗增加了ARDS患者的无呼吸机天数。然而,药物治疗ARDS缺乏成功,仍是该领域持续挑战。本文在简要总结既往ARDS临床试验经验基础上,重点讨论未来改进临床试验设计的机会,以最大化识别有益药物治疗的可能性。鉴于ARDS的异质性,需要预后富集和预测富集策略,基于严重程度和生物学特征将治疗靶向特定亚组患者。减少ARDS临床试验异质性的方法包括使用生理学、影像学和生物学标准为2期和3期试验选择患者。此外,对ARDS预防性临床试验设计以及在有创机械通气前早期治疗急性肺损伤患者的兴趣日益增长。本文还介绍了治疗ARDS有前景的新方法,包括联合治疗、细胞治疗和已在其他临床适应证中常规使用的低风险仿制药理化合物。
要点
- 肺保护性通气采用潮气量6 mL/kg预测体重、平台气道压<30 cm H2O,已降低ARDS死亡率。
- 对严重低氧的ARDS患者,神经肌肉阻滞和俯卧位进一步降低死亡率。
- 液体保守治疗增加ARDS患者无呼吸机天数。
- 药物治疗ARDS缺乏成功,仍是该领域持续挑战。
- 未来方向:基于严重程度和生物学特征进行预后与预测富集,用生理学、影像学和生物学标准选择2期和3期试验患者。
适用人群与场景
- ARDS患者,包括严重低氧患者。
诊断标准与关键阈值
- 使用生理学、影像学和生物学标准为2期和3期临床试验选择患者,以减少ARDS临床试验异质性。
处置流程与药物剂量
- 肺保护性通气:潮气量6 mL/kg预测体重,平台气道压<30 cm H2O。
- 对严重低氧的ARDS患者,使用神经肌肉阻滞和俯卧位。
- 液体保守治疗。
研究设计与关键结果
- 综述总结:肺保护性通气(潮气量6 mL/kg预测体重、平台压<30 cm H2O)降低ARDS死亡率;对严重低氧患者,神经肌肉阻滞和俯卧位进一步降低死亡率;液体保守治疗增加无呼吸机天数;药物治疗ARDS缺乏成功。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- ARDS患者采用肺保护性通气,潮气量6 mL/kg预测体重、平台气道压<30 cm H2O。
- 对严重低氧的ARDS患者,使用神经肌肉阻滞和俯卧位以进一步降低死亡率。
- 液体保守治疗以增加无呼吸机天数。
- 药物治疗ARDS目前缺乏成功,作者认为未来需通过预后和预测富集策略、基于严重程度和生物学特征选择患者来改进临床试验设计。
指南或共识出处
- 本文为综述,文中引用的指南或共识名称:原文未提及具体指南或共识名称。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
This year is the 50th anniversary of the first description of acute respiratory distress syndrome (ARDS). Since then, much has been learned about the pathogenesis of lung injury in ARDS, with an emphasis on the mechanisms of injury to the lung endothelium and the alveolar epithelium. In terms of treatment, major progress has been made in reducing mortality from ARDS with lung-protective ventilation, using a tidal volume of 6 mL per kg of predicted bodyweight and a plateau airway pressure of less than 30 cm H2O. In more severely hypoxaemic patients with ARDS, neuromuscular blockade and prone positioning have further reduced mortality, probably by extending the therapeutic effects of lung protective ventilation. Fluid-conservative therapy has also increased ventilator-free days in patients with ARDS. The lack of success of pharmacological therapies for ARDS, however, presents a continued challenge in the field. In addition to presenting a brief summary of previous experience with clinical trials in ARDS, we focus in this Review on future opportunities to improve clinical trial design to maximise the likelihood of identifying beneficial pharmacological therapies. In view of the heterogeneity in ARDS, both prognostic and predictive enrichment strategies are needed that target therapies toward specific subgroups of patients with ARDS on the basis of both severity and biology. Approaches to reducing heterogeneity in ARDS clinical trials include using physiological, radiographic, and biological criteria to select patients for both phase 2 and 3 trials. Additionally, interest is growing in the design of preventive clinical trials in ARDS and to initiate early treatment of patients with acute lung injury before the need for endotracheal intubation. We also present promising new approaches to treating ARDS, including combination therapies, cell-based therapies, and generic pharmacological compounds with low-risk profiles that are already in routine clinical use for other clinical indications.
参考来源
- Matthay MA, McAuley DF, Ware LB, et al. Clinical trials in acute respiratory distress syndrome: challenges and opportunities. Lancet Respir Med. 2017. PMID: 28664851. doi:10.1016/S2213-2600(17)30188-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。